Democratizing multiple myeloma CAR T cell therapy by in situ programming of virus-specific T cells”

Basic Information

Funding Cycle : 2022-2023
Name : Gabriel Kwong
Type of Award : Translational Research Award
Home Institution : Georgia Tech Research Corporation


The objective of this proposal is to develop antigen-presenting nanoparticles (APNs) to program virus-specific T cells with chimeric antigen receptors (CARs) targeting B-cell maturation antigen (BCMA) for the treatment of multiple myeloma (MM). Currently, CAR T cell therapy for MM is hindered by complex and costly manufacturing processes. By leveraging APNs to program circulating T cells in situ, this approach aims to bypass manufacturing challenges and broaden patient access to therapy. Unlike viral methods, APNs offer increased specificity by targeting only virus-specific T cells, minimizing off-target toxicity. Developed by integrating expertise in engineering pMHC molecules and CAR technology, APNs encapsulate CAR-encoded mRNA and decorate lipid nanoparticles with peptide-major histocompatibility complex (pMHC) molecules. This collaborative effort seeks to significantly reduce the cost of CAR T cell therapy and enhance its effectiveness in treating MM.

Why Become a Member

The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide.

The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.

Stay updated on our Events